Purdue Pharma L.P. Enters Agreement to Provide Low-Cost Opioid Use Disorder Treatment to Correctional Facilities for Incarcerated Individuals

STAMFORD, Conn.--(BUSINESS WIRE)--Purdue Pharma L.P. (“Purdue”) announced today that the company has partnered with MMCAP Infuse to provide buprenorphine and naloxone tablets CIII (generic Suboxone®), a medication for opioid use disorder (“MOUD”), at low cost to correctional facilities for incarcerated individuals with opioid use disorder. MMCAP Infuse is a national cooperative group purchasing organization operated by the State of Minnesota, Office of State Procurement, for government faciliti